Cytokine storm and the prospects for immunotherapy with COVID-19.
Cleve Clin J Med
; 87(7): 389-393, 2020 Jun 30.
Article
in English
| MEDLINE | ID: covidwho-250496
ABSTRACT
Knowledge about the pathobiology of SARS-CoV-2 as it interacts with immune defenses is limited. SARS-CoV-2 is spread by droplets that come into contact with mucous membranes. COVID-19 is characterized by 2 or 3 stages most patients who recover experience 2 stages of illness commencing with an asymptomatic or paucisymptomatic incubation period, followed by a nonsevere symptomatic illness lasting for several weeks, occurring in about 80% of those infected. In the remainder, a third phase marked by a severe respiratory illness, often accompanied by multisystem dysfunction, coagulopathy, and shock is observed. This phase of the illness is characterized by hypercytokinemic inflammation and is often referred to as "cytokine storm." While the immunopathogenesis remains unclear, prospects of treating this severe phase of the illness with immunotherapy are evolving, with some treatments showing promise.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Pandemics
/
Betacoronavirus
/
Cytokine Release Syndrome
/
Immunologic Factors
/
Immunotherapy
/
Inflammation
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Cleve Clin J Med
Journal subject:
Medicine
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS